Clinical Trial

A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HM11260C in patients with type 2 diabetes mellitus inadequately controlled with metformin and dapagliflozin
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-14
Trial Details
NCT Number NCT07379333
Lead Sponsor Hanmi Pharmaceutical Company Limited
Conditions Type 2 Diabetes
Enrollment 118 participants
Start Date 2026-04-13
Primary Completion 2027-11 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-13